Holen Sie sich die Stockscreener-App
2.17
2.84%
0.06
Handel nachbörslich:
2.18
0.01
+0.46%
Schlusskurs vom Vortag:
$2.11
Offen:
$2.14
24-Stunden-Volumen:
10,496
Relative Volume:
0.40
Marktkapitalisierung:
$15.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.6903
EPS:
-0.8066
Netto-Cashflow:
-
1W Leistung:
-6.06%
1M Leistung:
-27.67%
6M Leistung:
-29.11%
1J Leistung:
-37.10%
1-Tages-Spanne:
$2.10
$2.17
1-Wochen-Bereich:
$2.10
$2.35
52-Wochen-Spanne:
$2.05
$3.78
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Vergleichen Sie NRXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.17 | 15.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Chronic Idiopathic Constipation Clinical Trials and Pipeline - openPR
Critical Contrast: NeurAxis (NASDAQ:NRXS) & Zynex (NASDAQ:ZYXI) - Defense World
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Analyzing NeurAxis (NASDAQ:NRXS) and Masimo (NASDAQ:MASI) - Defense World
End Of January 2025 Portfolio Review - substack.com
FDA Clears NeurAxis’ Self-Inflating Balloon Device - MPO-mag
Financial Contrast: NeurAxis (NASDAQ:NRXS) versus ENDRA Life Sciences (NASDAQ:NDRA) - Defense World
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
Intapp to announce fiscal second quarter 2025 financial results on February 4, 2025 - The Manila Times
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
AAR Corporation (NYSE: AIR) Issues Press Release and Slide Presentation on Q2 2025 Financial Results - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com
Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
NeurAxis (NASDAQ:NRXS) Shares Down 4.1% – What’s Next? - Defense World
Model N Appoints New Chief Executive Officer, Bret Connor - The Manila Times
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - GlobeNewswire
NeurAxis CEO to Present at Lytham Partners 2025 Healthcare Investor Summit - StockTitan
MicroCap Opportunities 2024 Year-End Portfolio Update - substack.com
FDA Approvals News Live Feed - StockTitan
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com
Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire
NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan
FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag
Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com
Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa
Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria
Neuraxis secures $5 million in preferred stock sale - Investing.com
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
Kapitalisierung:
|
Volumen (24h):